Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia

Critical examination of confounds

Thomas W. Weickert, Terry E. Goldberg, Stefano Marenco, Llewellyn B. Bigelow, Michael F. Egan, Daniel Weinberger

Research output: Contribution to journalArticle

Abstract

Although previous studies report cognitive improvement following atypical antipsychotic administration in schizophrenia (SC), few placebo-controlled within-subject studies with examination of confounds (symptom reduction, cooperation, learning, and outliers) have been reported. The present study examines the effects of atypicals and confounds upon cognition in SC. The hypothesis tested was that relative to placebo, atypicals as a general class of medication would elicit cognitive improvement in SC. In all, 19 patients with SC (15 males) completed the double-blind, counterbalanced, randomized within-subject study of the effects of atypical antipsychotics (risperidone, clozapine, olanzapine, or quetiapine) vs placebo administration upon cognitive performance in the domains of executive function, attention, memory, language, visual perception, and general intellect. Significant cognitive improvement during atypical antipsychotic administration relative to placebo withdrawal occurred in most cognitive domains with robust improvements in intelligence (p = 0.001), memory (p = 0.0009), and fluency (p < 0.002) even after outliers and unmotivated performances were excluded. These findings suggest that relative to placebo withdrawal, atypicals improve cognitive performance in SC. However, this finding may not be specific to atypicals, since analogous studies of typicals have not been performed.

Original languageEnglish (US)
Pages (from-to)1491-1500
Number of pages10
JournalNeuropsychopharmacology
Volume28
Issue number8
DOIs
StatePublished - Aug 2003
Externally publishedYes

Fingerprint

Antipsychotic Agents
Schizophrenia
Placebos
olanzapine
Therapeutics
Visual Perception
Risperidone
Clozapine
Executive Function
Intelligence
Cognition
Language
Learning

Keywords

  • Antipsychotic agents
  • Cognition
  • Dopamine
  • Learning
  • Placebo
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia : Critical examination of confounds. / Weickert, Thomas W.; Goldberg, Terry E.; Marenco, Stefano; Bigelow, Llewellyn B.; Egan, Michael F.; Weinberger, Daniel.

In: Neuropsychopharmacology, Vol. 28, No. 8, 08.2003, p. 1491-1500.

Research output: Contribution to journalArticle

Weickert, Thomas W. ; Goldberg, Terry E. ; Marenco, Stefano ; Bigelow, Llewellyn B. ; Egan, Michael F. ; Weinberger, Daniel. / Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia : Critical examination of confounds. In: Neuropsychopharmacology. 2003 ; Vol. 28, No. 8. pp. 1491-1500.
@article{ef7fcdd171994a8ea46cee48f1563e2d,
title = "Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: Critical examination of confounds",
abstract = "Although previous studies report cognitive improvement following atypical antipsychotic administration in schizophrenia (SC), few placebo-controlled within-subject studies with examination of confounds (symptom reduction, cooperation, learning, and outliers) have been reported. The present study examines the effects of atypicals and confounds upon cognition in SC. The hypothesis tested was that relative to placebo, atypicals as a general class of medication would elicit cognitive improvement in SC. In all, 19 patients with SC (15 males) completed the double-blind, counterbalanced, randomized within-subject study of the effects of atypical antipsychotics (risperidone, clozapine, olanzapine, or quetiapine) vs placebo administration upon cognitive performance in the domains of executive function, attention, memory, language, visual perception, and general intellect. Significant cognitive improvement during atypical antipsychotic administration relative to placebo withdrawal occurred in most cognitive domains with robust improvements in intelligence (p = 0.001), memory (p = 0.0009), and fluency (p < 0.002) even after outliers and unmotivated performances were excluded. These findings suggest that relative to placebo withdrawal, atypicals improve cognitive performance in SC. However, this finding may not be specific to atypicals, since analogous studies of typicals have not been performed.",
keywords = "Antipsychotic agents, Cognition, Dopamine, Learning, Placebo, Schizophrenia",
author = "Weickert, {Thomas W.} and Goldberg, {Terry E.} and Stefano Marenco and Bigelow, {Llewellyn B.} and Egan, {Michael F.} and Daniel Weinberger",
year = "2003",
month = "8",
doi = "10.1038/sj.npp.1300216",
language = "English (US)",
volume = "28",
pages = "1491--1500",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia

T2 - Critical examination of confounds

AU - Weickert, Thomas W.

AU - Goldberg, Terry E.

AU - Marenco, Stefano

AU - Bigelow, Llewellyn B.

AU - Egan, Michael F.

AU - Weinberger, Daniel

PY - 2003/8

Y1 - 2003/8

N2 - Although previous studies report cognitive improvement following atypical antipsychotic administration in schizophrenia (SC), few placebo-controlled within-subject studies with examination of confounds (symptom reduction, cooperation, learning, and outliers) have been reported. The present study examines the effects of atypicals and confounds upon cognition in SC. The hypothesis tested was that relative to placebo, atypicals as a general class of medication would elicit cognitive improvement in SC. In all, 19 patients with SC (15 males) completed the double-blind, counterbalanced, randomized within-subject study of the effects of atypical antipsychotics (risperidone, clozapine, olanzapine, or quetiapine) vs placebo administration upon cognitive performance in the domains of executive function, attention, memory, language, visual perception, and general intellect. Significant cognitive improvement during atypical antipsychotic administration relative to placebo withdrawal occurred in most cognitive domains with robust improvements in intelligence (p = 0.001), memory (p = 0.0009), and fluency (p < 0.002) even after outliers and unmotivated performances were excluded. These findings suggest that relative to placebo withdrawal, atypicals improve cognitive performance in SC. However, this finding may not be specific to atypicals, since analogous studies of typicals have not been performed.

AB - Although previous studies report cognitive improvement following atypical antipsychotic administration in schizophrenia (SC), few placebo-controlled within-subject studies with examination of confounds (symptom reduction, cooperation, learning, and outliers) have been reported. The present study examines the effects of atypicals and confounds upon cognition in SC. The hypothesis tested was that relative to placebo, atypicals as a general class of medication would elicit cognitive improvement in SC. In all, 19 patients with SC (15 males) completed the double-blind, counterbalanced, randomized within-subject study of the effects of atypical antipsychotics (risperidone, clozapine, olanzapine, or quetiapine) vs placebo administration upon cognitive performance in the domains of executive function, attention, memory, language, visual perception, and general intellect. Significant cognitive improvement during atypical antipsychotic administration relative to placebo withdrawal occurred in most cognitive domains with robust improvements in intelligence (p = 0.001), memory (p = 0.0009), and fluency (p < 0.002) even after outliers and unmotivated performances were excluded. These findings suggest that relative to placebo withdrawal, atypicals improve cognitive performance in SC. However, this finding may not be specific to atypicals, since analogous studies of typicals have not been performed.

KW - Antipsychotic agents

KW - Cognition

KW - Dopamine

KW - Learning

KW - Placebo

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0042887005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042887005&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1300216

DO - 10.1038/sj.npp.1300216

M3 - Article

VL - 28

SP - 1491

EP - 1500

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 8

ER -